USPTO serial 79190479
FLITRIAQ
Reviewed by CopyMark Law Group
Reg. 5111779Status 404
- Filing date
- Status date
- Registration date
- Jan 3, 2017
- Examiner
- BENMAMAN, ALICE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FLITRIAQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; anti-fungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 18, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| May 31, 2025 | Further Decision Processed by IB | — | |
| Apr 8, 2025 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Apr 8, 2025 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Apr 8, 2025 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Mar 14, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 14, 2023 | C71T | CANCELLED SECTION 71 | — |
| May 12, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 24, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 24, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 2, 2017 | GPAR | GRANT OF PROTECTION CREATED, TO BE SENT TO IB | — |
| Jan 3, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 18, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 28, 2016 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 7, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 6, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 26, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 22, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 18, 2016 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Aug 18, 2016 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |